Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen ...

When you've finished reading about the winning Targeted Treatments, why not take a look at the other brilliant winning ...

To find out if you're eligible for the Shingles vaccine, details can be found here: Dr Kas discussed the shingles rash and ...

THERE are few things as satisfying as scratching an itch. But when your itch keeps recurring and starts to affect your day-to ...

Drs Chris and Xand continue their conversation about dry skin with Dr Tess McPherson, Associate Professor of Paediatric and Adolescent Dermatology at the University of Oxford.

Actress Tori Spelling and board certified dermatologist Dr. Adam Friedman are helping raise awareness of Eczema and encourage those who are struggling with it to reach ...

Network meta-analysis of five studies compares chronic hand eczema monotherapies, ranking ten treatments by HECSI score ...

Patients with moderate-to-severe AD can experience symptoms that disrupt sleep, thus impacting their daily activities and quality of life, said Druhan Howell, MD, a pediatric allergist and ...

Adults with atopic dermatitis experienced improvements through 16 weeks of treatment with rezpegaldesleukin, according to an abstract presented at the American College of Allergy, Asthma & Immunology ...

Dermatologists’ growing interest in training comes amid broader growth in integrative medicine — and uncertainties about ...

Nektar Therapeutics (NASDAQ:NKTR) is among the hottest SMID-cap stocks so far in 2025. On November 10, Oppenheimer analyst Jay Olson reaffirmed his Outperform rating on Nektar The ...

Dr. King calls this gel cream moisturizer "perfect" for dry skin. You can thank a number of ingredients for that. "It ...